Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2019 to Jul 2024
Molecular Devices Introduces Complete High-Content Screening
Solution
SUNNYVALE, Calif., June 14 /PRNewswire-FirstCall/ -- Molecular Devices
Corporation (NASDAQ:MDCC) today announced the introduction of a new suite of
powerful turnkey tools for High-Content Screening (HCS). This integrated series
of high-content imaging solutions consists of a new, cost-effective imaging
platform, ImageXpress MICRO (TM), and three new software packages,
MetaXpress(TM) for image acquisition, Application Modules for automated image
analysis, and AcuityXpress(TM), a powerful cellular informatics package. These
products are the result of the integration of Molecular Devices' scientific
knowledge and the expertise secured through its Universal Imaging and Axon
Instruments acquisitions. The launch follows Molecular Devices' acquisition in
March of the Transfluor(R) technology from Xsira Pharmaceuticals. The formal
introduction of Transfluor and the HCS product suite is slated to coincide with
the Second Annual Practical Experiences of High-Content Screening Symposium,
June 16-17, 2005 in London, England.
The ImageXpress MICRO is a modular, high-resolution CCD imager with upgradeable
options such as laser auto-focus for rapid plate-scanning and transmitted light
for bright field utility. MetaXpress, which utilizes Universal Imaging's widely
used MetaMorph(R) acquisition and analysis software as a backbone, provides a
uniform, simplified, and flexible hardware control and image acquisition
interface for all Molecular Devices' high-content imaging systems, including
the new ImageXpress MICRO and the previously commercialized ImageXpress(R)
5000A and Discovery-1(TM) systems.
The eleven Application Modules are fully validated, assay-specific image
analysis applications integrated with MetaXpress, enabling turnkey
configuration and operation of image segmentation and analysis. Lastly,
AcuityXpress provides powerful statistical and data visualization tools,
including automatic determination of IC50s, EC50s and Z' values, as well as the
ability to drill-down analysis data to the original images. MetaXpress, the
Application Modules and AcuityXpress are seamlessly integrated with
MDCStore(TM), an open API enterprise-level database for streamlined image and
data management.
Commenting on the launch, Dr. Michael Sjaastad, Director of Marketing for
Imaging Products at Molecular Devices, stated, "We're extremely excited about
the launch of our new HCS tools as we now offer a complete, cost-effective
solution to customers looking to perform high-content screening. The modularity
of the package allows each customer to purchase the level of capacity they need
for their application, whether they're running 5,000 or 50,000 samples a day.
With this introduction, we anticipate an increase in the adoption and
implementation of high-content screening into drug discovery by pharmaceutical
and biotech companies."
In conjunction with this launch, Molecular Devices is releasing its
Transfluor(R) GPCR activation assay, Transfluor general technology licenses and
reagents. The collection of Transfluor reagents includes cell lines stably
expressing Beta-arrestin-GFP and plasmids for constructing custom cell lines.
Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research. The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in genomics,
proteomics and parallel chemistry to facilitate the high-throughput and
cost-effective identification and evaluation of drug candidates. The Company's
solutions are based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry. Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.
This press release contains "forward-looking" statements, including statements
related to the prospects for or potential customer use of the ImageXpress MICRO
(TM), MetaXpress(TM), Application Modules, and AcuityXpress(TM) products. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "expects," "will," and similar expressions
are intended to identify forward-looking statements. There are a number of
important factors that could cause the results of Molecular Devices Corporation
to differ materially from those indicated by these forward-looking statements,
including, among others, risks related to the development of new products and
other risks detailed from time to time in the Company's SEC reports, including
its Quarterly Report on Form 10-Q for the quarter ended March 31, 2005.
Molecular Devices Corporation does not undertake any obligation to update
forward-looking statements.
DATASOURCE: Molecular Devices Corporation
CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533
Web site: http://www.moleculardevices.com/